These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19876587)

  • 1. Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.
    Sai JK; Suyama M; Kubokawa Y; Matsumura Y; Inami K; Watanabe S
    J Gastroenterol; 2010 Mar; 45(3):335-41. PubMed ID: 19876587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?
    Ashizawa N; Hashimoto T; Miyake T; Shizuku T; Imaoka T; Kinoshita Y
    J Gastroenterol Hepatol; 2006 Apr; 21(4):767-71. PubMed ID: 16677167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
    Yamawaki H; Futagami S; Kaneko K; Agawa S; Higuchi K; Murakami M; Wakabayashi M; Sakasegawa N; Kodaka Y; Ueki N; Gudis K; Kawamoto C; Iwakiri K
    Digestion; 2019; 99(4):283-292. PubMed ID: 30391941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of low-fat diet against dyspepsia associated with nonalcoholic mild pancreatic disease diagnosed using the Rosemont criteria.
    Maruki J; Sai JK; Watanabe S
    Pancreas; 2013 Jan; 42(1):49-52. PubMed ID: 22836859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents.
    Ishikura H; Nishimura S; Matsunami M; Tsujiuchi T; Ishiki T; Sekiguchi F; Naruse M; Nakatani T; Kamanaka Y; Kawabata A
    Life Sci; 2007 May; 80(21):1999-2004. PubMed ID: 17433371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats.
    Yuasa C; Irimura K; Oda M; Fukui K; Oka T
    J Pharm Pharmacol; 1999 Jul; 51(7):867-71. PubMed ID: 10467964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate.
    Beckh K; Weidenbach H; Weidenbach F; Müller R; Adler G
    Int J Pancreatol; 1991; 10(3-4):197-205. PubMed ID: 1787334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC).
    Ramsey ML; Nuttall J; Hart PA;
    Trials; 2019 Aug; 20(1):501. PubMed ID: 31412955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
    Jia D; Taguchi M; Otsuki M
    Pancreas; 2005 Jan; 30(1):54-61. PubMed ID: 15632700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis.
    Ino Y; Arita Y; Akashi T; Kimura T; Igarashi H; Oono T; Furukawa M; Kawabe K; Ogoshi K; Ouchi J; Miyahara T; Takayanagi R; Ito T
    World J Gastroenterol; 2008 Nov; 14(41):6382-7. PubMed ID: 19009656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension.
    Maekawa A; Kakizoe Y; Miyoshi T; Wakida N; Ko T; Shiraishi N; Adachi M; Tomita K; Kitamura K
    J Hypertens; 2009 Jan; 27(1):181-9. PubMed ID: 19145783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EUS to detect evidence of pancreatic disease in patients with persistent or nonspecific dyspepsia.
    Sahai AV; Mishra G; Penman ID; Williams D; Wallace MB; Hadzijahic N; Pearson A; Vanvelse A; Hoffman BJ; Hawes RH
    Gastrointest Endosc; 2000 Aug; 52(2):153-9. PubMed ID: 10922084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of camostat mesilate for the treatment of advanced diabetic nephropathy.
    Matsubara M; Taguma Y; Kurosawa K; Hotta O; Suzuki K; Ishizaki M
    J Lab Clin Med; 1990 Aug; 116(2):206-10. PubMed ID: 2394938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of proteinase inhibitor camostat mesilate on nephrotic syndrome with diabetic nephropathy.
    Onbe T; Makino H; Kumagai I; Haramoto T; Murakami K; Ota Z
    J Diabet Complications; 1991; 5(2-3):167-8. PubMed ID: 1770033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral protease inhibitor administration on gallbladder motility in patients with mild chronic pancreatitis.
    Sugiyama M; Atomi Y; Wada N; Kuroda A; Muto T
    J Gastroenterol; 1997 Jun; 32(3):374-9. PubMed ID: 9213253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats.
    Jia D; Taguchi M; Otsuki M
    Metabolism; 2005 May; 54(5):619-27. PubMed ID: 15877292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients].
    Freise J; Melzer P; Schmidt FW; Horbach L
    Z Gastroenterol; 1986 Apr; 24(4):200-11. PubMed ID: 3087076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Low-Dose Amitriptyline on Epigastric Pain Syndrome in Functional Dyspepsia Patients.
    Liu J; Jia L; Jiang SM; Zhou WC; Liu Y; Xu J
    Dig Dis Sci; 2021 Feb; 66(2):521-525. PubMed ID: 32166624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gabexate mesilate on serum inflammatory cytokines in rats with acute necrotizing pancreatitis.
    Chen CC; Wang SS; Tsay SH; Lee FY; Lu RH; Chang FY; Lee SD
    Cytokine; 2006 Jan; 33(2):95-9. PubMed ID: 16473521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.
    Okuno M; Akita K; Moriwaki H; Kawada N; Ikeda K; Kaneda K; Suzuki Y; Kojima S
    Gastroenterology; 2001 Jun; 120(7):1784-800. PubMed ID: 11375959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.